Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers
Home › KY › WILLIAMSTOWN › ST ELIZABETH MEDICAL CENTER, INC

ST ELIZABETH MEDICAL CENTER, INC

NPI: 1114974813 · WILLIAMSTOWN, KY 41097 · Critical Access Hospital · NPI assigned 05/28/2006

$35.42M
Total Medicaid Paid
394,581
Total Claims
301,753
Beneficiaries
192
Codes Billed
2018-01
First Month
2024-12
Last Month

Provider Details

Authorized OfficialRITCHEY-BALDWIN, LORI (CFO (INTERIM))
NPI Enumeration Date05/28/2006

Related Entities

Other providers sharing the same authorized official: RITCHEY-BALDWIN, LORI

ProviderCityStateTotal Paid
ST ELIZABETH MEDICAL CENTER, INC EDGEWOOD KY $188.25M
ST ELIZABETH MEDICAL CENTER, INC FLORENCE KY $65.44M
ST ELIZABETH MEDICAL CENTER, INC FORT THOMAS KY $45.99M
ST ELIZABETH MEDICAL CENTER, INC LAWRENCEBURG IN $4.66M
ST ELIZABETH MEDICAL CENTER, INC ERLANGER KY $3.75M
ST ELIZABETH MEDICAL CENTER, INC EDGEWOOD KY $2.95M
ST. ELIZABETH MEDICAL CENTER, INC. EDGEWOOD KY $438.18

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 55,516 $4.41M
2019 51,146 $4.57M
2020 46,889 $4.42M
2021 56,001 $4.96M
2022 62,582 $5.45M
2023 67,681 $6.31M
2024 54,766 $5.29M

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
99283 Emergency department visit for the evaluation and management, moderate severity 27,755 24,883 $9.82M
99284 Emergency department visit for the evaluation and management, high severity 10,326 9,084 $5.87M
99285 Emergency department visit for the evaluation and management, high severity with immediate threat to life 5,578 4,287 $3.65M
96374 Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance 12,233 7,313 $1.62M
99282 Emergency department visit for the evaluation and management, low to moderate severity 7,407 7,003 $1.46M
74177 Computed tomography, abdomen and pelvis; with contrast material 4,258 3,928 $1.38M
96365 Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour 6,984 3,041 $925K
36415 Collection of venous blood by venipuncture 49,467 28,069 $757K
J3490 Unclassified drugs 19,439 8,960 $550K
96372 Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular 8,218 4,986 $548K
97110 Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion 9,507 3,241 $520K
96361 Intravenous infusion, hydration; each additional hour 11,315 5,491 $500K
99291 Critical care, evaluation and management of the critically ill patient, first 30-74 minutes 783 539 $477K
93005 Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report 8,310 7,359 $450K
71046 Radiologic examination, chest; 2 views 5,968 5,478 $412K
96375 Therapeutic injection; each additional sequential IV push 5,852 5,036 $369K
74176 Computed tomography, abdomen and pelvis; without contrast material 1,671 1,539 $358K
87636 Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B 2,354 2,227 $328K
71045 Radiologic examination, chest; single view 4,173 3,654 $304K
70450 Computed tomography, head or brain; without contrast material 2,999 2,632 $296K
96360 Intravenous infusion, hydration; initial, 31 minutes to 1 hour 2,871 1,008 $227K
72100 2,005 1,788 $208K
80053 Comprehensive metabolic panel 14,742 13,062 $185K
93306 Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete 438 412 $182K
73630 2,258 2,084 $173K
76705 Ultrasound, abdominal, real time with image documentation; limited 1,463 1,414 $164K
85025 Blood count; complete (CBC), automated, and automated differential WBC count 17,241 15,276 $161K
77067 Screening mammography, bilateral, including computer-aided detection 1,630 1,600 $146K
73564 1,298 1,152 $138K
73610 1,857 1,660 $137K
94640 Pressurized or nonpressurized inhalation treatment for acute airway obstruction 748 703 $133K
73130 1,641 1,491 $131K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe 2,931 2,720 $112K
73030 1,430 1,201 $109K
96376 1,467 1,309 $102K
76830 Ultrasound, transvaginal 740 691 $96K
72148 Magnetic resonance imaging, lumbar spine; without contrast material 498 458 $95K
84484 6,917 4,345 $92K
71275 Computed tomographic angiography, chest, with contrast material 507 465 $90K
80048 Basic metabolic panel (calcium, ionized) 9,001 8,174 $86K
97161 942 902 $83K
71260 Computed tomography, thorax, diagnostic; with contrast material 436 361 $80K
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml 7,472 6,268 $76K
84702 4,680 4,230 $76K
84443 Thyroid stimulating hormone (TSH) 3,705 3,593 $75K
73110 972 882 $73K
71271 689 621 $60K
76856 Ultrasound, pelvic (nonobstetric), real time with image documentation; complete 735 717 $51K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 732 683 $48K
85027 6,729 6,303 $46K
83690 5,403 4,941 $44K
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed 1,470 1,438 $43K
74018 559 513 $43K
87651 Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe 1,165 1,136 $41K
80061 Lipid panel 2,732 2,664 $41K
82565 1,634 851 $39K
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 678 655 $39K
87804 Infectious agent antigen detection by immunoassay; Influenza, each type 1,456 994 $36K
70553 Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences 93 82 $34K
12001 302 288 $34K
83880 856 773 $34K
83605 2,759 2,171 $34K
29125 199 190 $31K
77063 Screening digital breast tomosynthesis, bilateral 1,128 1,022 $31K
71250 360 292 $29K
81001 6,456 5,964 $27K
82077 862 798 $27K
87631 182 177 $27K
90471 Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine 480 467 $26K
87086 Culture, bacterial; quantitative colony count, urine 2,870 2,643 $26K
99281 Emergency department visit for the evaluation and management, self-limited or minor 218 212 $25K
83036 Hemoglobin; glycosylated (A1C) 1,984 1,937 $24K
87430 1,235 1,149 $23K
82803 778 691 $23K
73502 275 248 $21K
96366 Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour 269 233 $21K
82962 2,605 1,665 $19K
80076 1,905 1,799 $18K
72050 180 149 $18K
85379 1,506 1,463 $18K
80306 995 928 $18K
85610 3,350 2,311 $17K
J1885 Injection, ketorolac tromethamine, per 15 mg 4,731 3,959 $16K
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe 378 369 $16K
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe 377 368 $16K
84703 1,356 1,274 $16K
11042 Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm 75 27 $15K
73140 210 188 $14K
87040 1,105 637 $14K
84439 1,191 1,165 $14K
J2405 Injection, ondansetron hydrochloride, per 1 mg 6,564 5,248 $14K
73080 209 189 $13K
82607 610 590 $13K
J2270 Injection, morphine sulfate, up to 10 mg 4,247 3,066 $13K
A9575 Injection, gadoterate meglumine, 0.1 ml 302 230 $12K
J0131 Injection, acetaminophen, not otherwise specified,10 mg 663 439 $12K
83735 1,473 1,300 $12K
96413 Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance 33 24 $11K
97140 Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) 332 145 $11K
90715 348 283 $11K
81003 3,011 2,799 $10K
73562 120 107 $10K
J1200 Injection, diphenhydramine hcl, up to 50 mg 2,245 1,728 $9K
87077 692 593 $8K
72125 Computed tomography, cervical spine; without contrast material 77 74 $8K
97112 Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination 137 60 $8K
J1642 Injection, heparin sodium, (heparin lock flush), per 10 units 600 236 $8K
99211 Office or other outpatient visit for the evaluation and management of an established patient, minimal severity 610 487 $7K
86140 1,108 1,009 $6K
76770 59 55 $6K
10060 56 54 $6K
87186 542 502 $5K
76536 39 38 $5K
82746 271 267 $5K
84145 189 178 $5K
M0243 Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring 17 17 $5K
97162 42 40 $5K
A9577 Injection, gadobenate dimeglumine (multihance), per ml 152 109 $5K
96367 61 56 $5K
12002 45 27 $4K
93971 44 40 $4K
Q0162 Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen 1,496 1,441 $4K
G0463 Hospital outpatient clinic visit for assessment and management of a patient 175 128 $4K
93225 31 26 $4K
85652 1,171 1,079 $4K
70498 27 24 $4K
82728 181 178 $4K
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies 120 118 $3K
J1756 Injection, iron sucrose, 1 mg 35 12 $3K
J1100 Injection, dexamethasone sodium phosphate, 1 mg 1,030 871 $3K
83540 359 351 $3K
G0297 Low dose ct scan (ldct) for lung cancer screening 66 56 $3K
J0696 Injection, ceftriaxone sodium, per 250 mg 1,117 685 $3K
73721 Magnetic resonance imaging, any joint of lower extremity; without contrast material 14 14 $2K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 25 25 $2K
83550 210 206 $2K
80305 137 128 $2K
82570 278 242 $2K
J1030 Injection, methylprednisolone acetate, 40 mg 126 120 $2K
36591 16 12 $2K
12011 12 12 $2K
70491 12 12 $2K
85730 255 238 $2K
73090 16 15 $2K
87807 103 100 $2K
72070 15 13 $1K
J0780 Injection, prochlorperazine, up to 10 mg 133 119 $1K
J1790 Injection, droperidol, up to 5 mg 517 458 $1K
82805 39 36 $1K
73590 28 26 $1K
80074 24 24 $1K
93226 14 13 $1K
J7512 Prednisone, immediate release or delayed release, oral, 1 mg 561 493 $1K
80069 98 75 $1K
88305 Level IV - Surgical pathology, gross and microscopic examination 14 12 $934.64
87808 54 54 $914.49
80143 12 12 $886.88
J2930 Injection, methylprednisolone sodium succinate, up to 125 mg 104 38 $678.14
87522 Neg quan hep c or qual rna 12 12 $676.37
86901 79 74 $655.49
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 12 12 $651.13
86900 63 61 $629.28
86780 37 36 $484.61
G0279 Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) 14 12 $405.80
J2060 Injection, lorazepam, 2 mg 275 205 $403.54
84550 72 67 $323.57
G0475 Hiv antigen/antibody, combination assay, screening 14 14 $316.89
J1170 Injection, hydromorphone, up to 4 mg 172 148 $294.88
87088 29 29 $265.80
86803 12 12 $254.51
83516 12 12 $241.03
97010 30 13 $205.79
86038 12 12 $189.64
87340 12 12 $181.94
J0134 Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg 33 32 $158.26
J2272 Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg 63 53 $134.92
84156 29 27 $132.90
82248 23 16 $131.91
G1004 Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program 17 12 $131.72
82043 12 12 $127.95
82247 19 12 $111.59
82550 12 12 $110.33
87205 28 25 $102.37
86430 14 13 $90.97
84100 22 18 $78.25
Q0163 Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen 35 35 $27.29
J2550 Injection, promethazine hcl, up to 50 mg 30 28 $22.16
J3010 Injection, fentanyl citrate, 0.1 mg 14 12 $15.66
J2765 Injection, metoclopramide hcl, up to 10 mg 26 25 $13.76
G8979 Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting 37 34 $0.00
G8978 Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals 33 31 $0.00
Q0244 Injection, casirivimab and imdevimab, 1200 mg 15 15 $0.00